Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Cash from Financing Activities (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Cash from Financing Activities data on record, last reported at $37.5 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities rose 8166.96% year-over-year to $37.5 million; the TTM value through Sep 2025 reached $55.1 million, up 59.81%, while the annual FY2024 figure was $36.7 million, 38.22% up from the prior year.
  • Cash from Financing Activities reached $37.5 million in Q3 2025 per BTAI's latest filing, up from $137000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $37.5 million in Q3 2025 and bottomed at $50000.0 in Q4 2022.
  • Average Cash from Financing Activities over 4 years is $12.0 million, with a median of $4.8 million recorded in 2024.
  • The widest YoY moves for Cash from Financing Activities: up 8166.96% in 2025, down 97.42% in 2025.
  • A 4-year view of Cash from Financing Activities shows it stood at $50000.0 in 2022, then surged by 4146.0% to $2.1 million in 2023, then surged by 101.41% to $4.3 million in 2024, then soared by 777.74% to $37.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $37.5 million in Q3 2025, $137000.0 in Q2 2025, and $13.2 million in Q1 2025.